All News
Filter News
Found 297 articles
-
Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa
6/22/2022
Krystal Biotech, Inc. announced the submission of a Biologics License Application to the U.S. Food and Drug Administration seeking approval of B-VEC for the treatment of patients with dystrophic epidermolysis bullosa.
-
PharmaTher Announces Positive Results from Study of KETABET™ for Depression
6/7/2022
KETABET™ ( Ketamine and Betaine) shown effectiveness as measured by the Clinician Administered Dissociative States Scale.
-
Krystal Biotech to Present at Goldman Sachs 43rd Annual Global Healthcare Conference
6/7/2022
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference in Rancho Palos Verdes, California.
-
Mirati Therapeutics presented the first clinical data demonstrating CNS-specific activity of a KRASG12C inhibitor in patients with NSCLC with active and untreated CNS metastases.
-
New Late-Breaking Data on Investigational Adagrasib Show Regression of Central Nervous System (CNS) Metastases in Patients with KRASG12C-mutated Non-Small Cell Lung Cancer (NSCLC) with Active, Untreated CNS Metastases
6/6/2022
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced results of a prospective analysis from the Phase 1b cohort of the KRYSTAL-1 study evaluating intracranial (IC) responses of adagrasib in patients with KRASG12C-mutated non-small cell lung cancer (NSCLC) with active and untreated central nervous system (CNS) metastases.
-
Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Facilitator Training Program
6/3/2022
Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced the team of 28 esteemed faculty and advisors who will lead the Company’s EMBARK Psychedelic Facilitator Training Program.
-
Investigators from US Oncology Research, The US Oncology Network and Ontada Present Data Highlighting Key Advances and Insights at the 2022 American Society of Clinical Oncology Annual Meeting
6/3/2022
During the scientific program of the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, principal investigators from US Oncology Research, The US Oncology Network (The Network) and Ontada® will present detailed results from more than 80 studies.
-
Cybin to Host Key Opinion Leader Webinar on June 9, 2022
6/2/2022
Featured speakers include Dr. John Krystal, Yale School of Medicine, and Dr. David Nutt, Imperial College London.
-
EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AT THE 36TH ANNUAL SLEEP 2022 MEETING
6/2/2022
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today a total of seven poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO® CIV) will be given at the 36th annual meeting of the Associated Professional Sleep Societies (SLEEP 2022).
-
Mirati Therapeutics' adagrasib is going up against Amgen’s Lumakras in the KRAS race, and according to Friday pre-market trading, the results shared Thursday don't seem to be enough for investors.
-
Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer
5/26/2022
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced positive results from the registration-enabling Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib 600 mg BID in patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy.
-
Mirati Therapeutics Submits Marketing Authorization Application to the European Medicines Agency for Investigational Adagrasib as a Treatment for Previously-Treated KRASG12C-mutated Non-Small Cell Lung Cancer
5/19/2022
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for adagrasib for the treatment of patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy.
-
Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting
5/19/2022
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, is pleased to present new data entitled “GEM-3: phase 3 safety and immunogenicity results of beremagene geperpavec (B-VEC), an investigational, topical gene therapy for dystrophic epidermolysis bullosa (DEB)” at the Society for Investigative Dermatology 2022 Annual Meeting.
-
Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
5/9/2022
Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system disorders, announced the completion of its U.S. acquisition of Sunosi® from Jazz Pharmaceuticals.
-
Krystal Biotech Announces First Quarter 2022 Financial Results and Reports Updates on Operational Progress
5/9/2022
Krystal Biotech, Inc., (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today reported financial results and key operational progress updates for the first quarter ending March 31, 2022.
-
Mirati Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Updates
5/4/2022
Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, reported financial results for the first quarter of 2022 and recent corporate updates.
-
Krystal Biotech to Participate in Bank of America Merrill Lynch Global Healthcare Conference
5/3/2022
Krystal Biotech, Inc. announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in the Bank of America Merrill Lynch Global Healthcare Conference.
-
Global KRAS Inhibitors Drug Market Clinical Trials Forecast 2028
4/29/2022
"Global KRAS Inhibitors Market & Clinical Trials Forecast 2028" Report Highlights.
-
Mirati Therapeutics to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib
4/27/2022
Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced the presentation of new clinical research showcasing the potential of its investigational KRASG12C inhibitor, adagrasib, in a study of patients with KRASG12C-mutated non-small cell lung cancer (NSCLC) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Krystal Biotech Announces Home Dosing in B-VEC Open Label Extension Study
4/11/2022
Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies, today announced that it plans to offer patients with dystrophic epidermolysis bullosa (DEB), who are enrolled in the GEM-3 open label extension study, the opportunity to be dosed in their homes by a health care professional (HCP).